Russell Investments Group Ltd. Takes Position in Stoke Therapeutics, Inc. $STOK

Key Points

• Russell Investments Group Ltd. purchased 16,119 shares of Stoke Therapeutics, Inc. for approximately $107,000, marking a significant investment in the company during the first quarter.
• Insider trading activity included General Counsel Jonathan Allan selling 6,345 shares, resulting in a 34.91% decrease in his holdings, while insider Barry Ticho also sold 5,501 shares, decreasing his position by 22.95%.
• The stock has a current market capitalization of $1.08 billion and several analysts have set price targets between $22.00 and $30.00, indicating a mostly positive outlook for future performance.

Russell Investments Group Ltd. bought a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 16,119 shares of the company's stock, valued at approximately $107,000.

Other institutional investors also recently bought and sold shares of the company. Nuveen LLC acquired a new position in Stoke Therapeutics during the 1st quarter worth about $719,000. Invesco Ltd. lifted its position in shares of Stoke Therapeutics by 117.0% in the first quarter. Invesco Ltd. now owns 26,183 shares of the company's stock valued at $174,000 after acquiring an additional 14,118 shares in the last quarter. Vanguard Group Inc. lifted its position in Stoke Therapeutics by 1.9% during the first quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company's stock worth $18,515,000 after buying an additional 53,004 shares during the period. US Bancorp DE increased its stake in Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company's stock worth $75,000 after acquiring an additional 11,108 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Stoke Therapeutics in the first quarter valued at about $267,000.

Insiders Place Their Bets

In related news, General Counsel Jonathan Allan sold 6,345 shares of the business's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $20.07, for a total value of $127,344.15. Following the sale, the general counsel directly owned 11,831 shares in the company, valued at $237,448.17. The trade was a 34.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Md Kaye sold 45,996 shares of the firm's stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $20.13, for a total value of $925,899.48. Following the transaction, the director owned 91,585 shares in the company, valued at $1,843,606.05. This trade represents a 33.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 107,719 shares of company stock valued at $2,063,359. 9.50% of the stock is owned by corporate insiders.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock traded up $1.61 during mid-day trading on Monday, hitting $22.29. The company's stock had a trading volume of 834,629 shares, compared to its average volume of 808,356. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $22.39. The business has a 50 day moving average price of $14.92 and a 200-day moving average price of $11.06. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of 26.12 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The company had revenue of $13.82 million for the quarter, compared to the consensus estimate of $31.51 million. On average, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. BTIG Research set a $28.00 price objective on Stoke Therapeutics and gave the company a "buy" rating in a research note on Monday, August 18th. Wedbush raised their price objective on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 13th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Finally, Chardan Capital reiterated a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Two analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $25.57.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.